(Q51563075)

English

Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption.

scientific article published in June 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10354963

Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10354963

lamivudine/zidovudine

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Moore KH

1

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10354963

Shaw S

2

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10354963

Laurent AL

3

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10354963

Lloyd P

4

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10354963

Duncan B

5

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10354963

Morris DM

6

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10354963

O'Mara MJ

7

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10354963

Pakes GE

8

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10354963

publication date

1 June 1999

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10354963

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10354963

39

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10354963

6

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10354963

593-605

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10354963

Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Cellular metabolism of (−) enantiomeric 2′-deoxy-3′-thiacytidine

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal.

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Clinical pharmacokinetics of zidovudine. An update

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Antiviral and immunological effects of escalating low doses of zidovudine in HIV-positive patients

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV disease

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

High-performance liquid chromatographic assay for 2'-deoxy-3'-thiacytidine in human serum

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Comparative pharmacokinetics of zidovudine (AZT) and its metabolite (G.AZT) in healthy subjects and HIV seropositive patients

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

The pharmacokinetics of lamivudine in patients with impaired hepatic function

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Renal disposition and drug interaction screening of (-)-2'-deoxy-3'-thiacytidine (3TC) in the isolated perfused rat kidney

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

The maternal-fetal transfer of lamivudine in the ex vivo human placenta

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008209

21 January 2018

Identifiers

10.1177/00912709922008209

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10354963

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10354963

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51563075&oldid=1584982479"